Not available
Quote | Epizyme Inc. (NASDAQ:EPZM)
Last: | $1.47 |
---|---|
Change Percent: | 0.0% |
Open: | $0 |
Close: | $1.47 |
High: | $0 |
Low: | $0 |
Volume: | 7,960 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Epizyme Inc. (NASDAQ:EPZM)
Epizyme press release ( NASDAQ: EPZM ): Q2 GAAP EPS of -$0.21. Revenue of $27.5M (+111.4% Y/Y). For further details see: Epizyme GAAP EPS of -$0.21, revenue of $27.5M
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
Message Board Posts | Epizyme Inc. (NASDAQ:EPZM)
Subject | By | Source | When |
---|---|---|---|
Expiration of the Offer (8/12/22) | Enterprising Investor | investorshub | 08/12/2022 1:31:51 PM |
Thank | Pt3 | investorshub | 06/28/2022 1:52:48 AM |
1.45 + 1 = 2.45 Is what I | JJL | investorshub | 06/28/2022 1:47:18 AM |
Jump in blindly what is this buyout 1.45 | Pt3 | investorshub | 06/27/2022 7:48:36 PM |
Retrace | JJL | investorshub | 06/27/2022 4:38:33 PM |
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...